Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053111 | 0.88 | FOLH1 (0.60) | FOLH1GSTK1GRM3ANPEPENPEP | |
| SCHEMBL3809808 | 0.81 | GRIK1 (0.51) | FOLH1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL12663338 | 0.81 | GSTK1 (0.55) | FOLH1HDAC1HDAC2GSTK1ANPEP | |
| SCHEMBL28186629 | 0.79 | FOLH1 (0.48) | FOLH1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL7839779 | 0.79 | FOLH1 (0.52) | FOLH1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL2230782 | 0.77 | CHRM1 (0.76) | FOLH1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL19819308 | 0.77 | FOLH1 (0.50) | FOLH1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5058030 | 0.77 | FOLH1 (0.64) | FOLH1GRM3ANPEPENPEP | |
| Bromide SCHEMBL7659007 | 0.75 | CHRM1 (0.73) | FOLH1CHRM1AKR1A1CHRM3HTR2A | |
| Hydrochloric Acid SCHEMBL27682490 | 0.75 | CHRM1 (0.73) | FOLH1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093453-B1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARM INC (US) | 2005-09-28 | — | — | EP | claimed |
| EP-1571141-A2 | Naaladase inhibitors useful as pharmaceutical compounds and compositions | GUILFORD PHARMACEUTICALS INC. (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | claimed |
| US-6806261-B2 | CONTROL RELEASE TRANSFORMING GROWTH FACTOR; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIPROLIFERATIVE AGENT | GUILFORD PHARMACEUTICALS INC. | 2004-10-19 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1202717-B1 | USE OF NAALADASE INHIBITORS FOR TREATING ANXIETY AND MEMORY DISORDERS | GUILFORD PHARM INC (US) | 2004-03-03 | — | — | EP | claimed |
| EP-1140048-B1 | USE OF NAALADASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN DISEASES | GUILFORD PHARM INC (US) | 2003-09-03 | — | — | EP | claimed |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | JACKSON PAUL F (US) | 2003-05-01 | — | — | US | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| US-20030013687-A1 | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-01-16 | — | — | US | claimed |
| US-6458775-B1 | N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) INHIBITORS ENZYME ACTIVITY, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH INHIBITORS, AND METHODS OF THEIR USE TO INHIBIT NAALADASE ENZYME ACTIVITY, THEREBY EFFECTING NEURONAL | GUILFORD PHARMACEUTICAL INC. | 2002-10-01 | — | — | US | claimed |
| US-6444657-B1 | 2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID; 2-(2-SULFANYLETHYL) PENTANEDIOIC ACID; EPITHELIAL TISSUE SCARRING, COLLAGEN VASCULAR DISEASE, FIBROPROLIFERATION, CONNECTIVE TISSUE DISORDER, RESPIRATORY DISTRESS SYNDROME; TGF REGULATOR | GUILFORD PHARMACEUTICALS INC. | 2002-09-03 | — | — | US | claimed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-6228888-B1 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2001-05-08 | — | — | US | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2000001668-A2 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | FOLH1 432/4885CHRM1 4202/4885AKR1A1 2351/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | FOLH1 262/4885CHRM1 4623/4885AKR1A1 1704/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885CHRM1 2560/4885AKR1A1 598/4885 |
| US-20030013687-A1 | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors | GRIN1, GRIN2A, GRIN2B | FOLH1 224/4885CHRM1 1466/4885AKR1A1 1291/4885 |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | NAALAD2, DNPEP, NAAA | FOLH1 22/4885CHRM1 4653/4885AKR1A1 1726/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | FOLH1 254/4885CHRM1 2871/4885AKR1A1 370/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | FOLH1 124/4885CHRM1 3702/4885AKR1A1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.